BioCentury
ARTICLE | Clinical News

Cerenis HDL: Phase II data

July 28, 2014 7:00 AM UTC

The open-label, Dutch Phase II SAMBA trial in 7 patients with familial primary hypoalphalipoproteinemia showed that IV CER-001 plus optimized LDL-C-lowering therapy significantly increased levels of A...